ANTICOV Trial Finds Nitazoxanide/Ciclesonide Drug Combination Does Not Reduce Hospitalisation Risk in Patients With Mild COVID-19

ANTICOV News, ANTICOV, NCT04920838

Feb 2022

Source PDF All Studies Meta AnalysisMeta

RCT with 462 nitazoxanide/ciclesonide and 443 paracetamol patients, up to 7 days from onset, showing no significant difference in progression. Minimal details, with the primary mortality outcome and treatment delay not being reported. This study is excluded in the after exclusion results of meta analysis: minimal details provided.

Important missing comments or errors? Let us know.

risk of progression, 187.7% higher, RR 2.88, p = 0.04, treatment 15 of 462 (3.2%), control 5 of 443 (1.1%), SpO2 ≤ 93% within 14 days.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

ANTICOV et al., 28 Feb 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with ciclesonide) - results of individual treatments may vary, trial NCT04920838 (history) (ANTICOV).

All Studies All Outcomes Submit Updates or Corrections

This Paper Nitazoxanide All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0